At Alaya.bio, we're developing a revolutionary targeting polymeric nanoparticle that enhances the transduction efficiency of quiescent cells such as T-cells, NK-cells, and stem cells. Our platform eliminates the need for activation factors or cytokines, resulting in reduced exhaustion of transduced cells while preserving their naive and memory phenotypes, leading to better clinical outcomes.
Employees: 11-50
Founded date: 2022
Investors 1
| Date | Name | Website |
| 14.09.2026 | Agoranov | agoranov.c... |
Mentions in press and media 2
| Date | Title | Description |
| 15.07.2024 | Nona Biosciences Enters into Collaboration Agreement with Alaya.bio to Advance CAR-T Cell Therapy | CAMBRIDGE, Mass., July 15, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical r... |
| 23.10.2023 | Alaya.bio Acquires Key Assets From Ixaka France | Alaya.bio, a Villejuif, France- and Cambridge, MA-based in vivo gene delivery biotech company, acquired all assets previously owned by Ixaka France, a preclinical-stage immunotherapy biotech company specializing in in vivo CAR T-cell therap... |